IL274202A - Antibodies against Glyco-Moc1 and uses thereof - Google Patents
Antibodies against Glyco-Moc1 and uses thereofInfo
- Publication number
- IL274202A IL274202A IL274202A IL27420220A IL274202A IL 274202 A IL274202 A IL 274202A IL 274202 A IL274202 A IL 274202A IL 27420220 A IL27420220 A IL 27420220A IL 274202 A IL274202 A IL 274202A
- Authority
- IL
- Israel
- Prior art keywords
- glyco
- muc1 antibodies
- muc1
- antibodies
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4725—Mucins, e.g. human intestinal mucin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/058036 WO2019083506A1 (fr) | 2017-10-24 | 2017-10-24 | Anticorps anti-glyco-muc1 et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
IL274202A true IL274202A (en) | 2020-06-30 |
Family
ID=66247577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL274202A IL274202A (en) | 2017-10-24 | 2020-04-23 | Antibodies against Glyco-Moc1 and uses thereof |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP3700936A4 (fr) |
JP (2) | JP7358367B2 (fr) |
KR (2) | KR20230165874A (fr) |
CN (1) | CN111479828B (fr) |
AU (1) | AU2017436815A1 (fr) |
BR (1) | BR112020008001A2 (fr) |
CA (1) | CA3078812A1 (fr) |
IL (1) | IL274202A (fr) |
MX (1) | MX2020004220A (fr) |
WO (1) | WO2019083506A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796498A (zh) * | 2022-01-27 | 2022-07-29 | 中国农业大学 | 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020146750A1 (en) * | 2000-03-30 | 2002-10-10 | Hoogenboom Hendricus R.J.M. | Mucin-1 specific binding members and methods of use thereof |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
EP2014302A1 (fr) * | 2007-07-12 | 2009-01-14 | Institut Curie | Anticorps spécifique à l'antigène Tn pour le traitement du cancer |
AU2008332296A1 (en) * | 2007-12-05 | 2009-06-11 | Kyowa Hakko Kirin Co., Ltd. | Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor |
CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
EP2281844A1 (fr) * | 2009-07-31 | 2011-02-09 | Glycotope GmbH | Anticorps MUC 1 |
US10208125B2 (en) * | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
KR102262720B1 (ko) * | 2014-04-28 | 2021-06-08 | 이카가쿠 소우야쿠 가부시키가이샤 | 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도 |
-
2017
- 2017-10-24 KR KR1020237040745A patent/KR20230165874A/ko not_active Application Discontinuation
- 2017-10-24 WO PCT/US2017/058036 patent/WO2019083506A1/fr unknown
- 2017-10-24 CA CA3078812A patent/CA3078812A1/fr active Pending
- 2017-10-24 CN CN201780097773.8A patent/CN111479828B/zh active Active
- 2017-10-24 MX MX2020004220A patent/MX2020004220A/es unknown
- 2017-10-24 AU AU2017436815A patent/AU2017436815A1/en active Pending
- 2017-10-24 EP EP17929557.1A patent/EP3700936A4/fr active Pending
- 2017-10-24 BR BR112020008001-2A patent/BR112020008001A2/pt unknown
- 2017-10-24 KR KR1020207014390A patent/KR102608763B1/ko active IP Right Grant
- 2017-10-24 JP JP2020543460A patent/JP7358367B2/ja active Active
-
2020
- 2020-04-23 IL IL274202A patent/IL274202A/en unknown
-
2023
- 2023-09-27 JP JP2023165289A patent/JP2024001073A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20200067885A (ko) | 2020-06-12 |
JP2021510307A (ja) | 2021-04-22 |
EP3700936A1 (fr) | 2020-09-02 |
EP3700936A4 (fr) | 2021-05-26 |
CN111479828B (zh) | 2024-07-05 |
JP7358367B2 (ja) | 2023-10-10 |
KR102608763B1 (ko) | 2023-11-30 |
JP2024001073A (ja) | 2024-01-09 |
MX2020004220A (es) | 2020-10-05 |
BR112020008001A2 (pt) | 2020-10-20 |
WO2019083506A1 (fr) | 2019-05-02 |
CA3078812A1 (fr) | 2019-05-02 |
KR20230165874A (ko) | 2023-12-05 |
AU2017436815A1 (en) | 2020-04-23 |
CN111479828A (zh) | 2020-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290842A (en) | Anti-cd73 antibodies and uses thereof | |
ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
IL272218A (en) | ANTI-SIRP-ALPHA ANTIBODIES AND RELATED METHODS | |
IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
IL266738A (en) | Novel antibodies and their uses | |
IL262095A (en) | Anti-pacap antibodies and their use | |
IL271477A (en) | Anti-cd166 antibodies and their uses | |
IL269134A (en) | Antibodies against PAR2 and their use | |
ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
IL272476A (en) | Anti-Apelin antibodies and their uses | |
IL266049A (en) | Antibodies against o1 and their uses | |
IL273157A (en) | Antibodies specific to AXL and their uses | |
IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
IL264417A (en) | Anti-o2 antibodies and their uses | |
IL266082A (en) | Anti-chikv antibodies and their use | |
GB201712032D0 (en) | Antibodies and uses thereof | |
IL274202A (en) | Antibodies against Glyco-Moc1 and uses thereof | |
GB201820334D0 (en) | Antibodies and their uses |